A open label phase II trial of cetuximab plus cisplatin in patients with recurrent or metastatic undifferentiated carcinoma of nasopharyngeal type: Results after three years.

Esma Kerboua,Amina Tahrat,Kamel Bouzid

A open label phase II trial of cetuximab plus cisplatin in patients with recurrent or metastatic undifferentiated carcinoma of nasopharyngeal type: Results after three years.

2015

Esma Kerboua
Amina Tahrat
Kamel Bouzid

e17021 Background: To evaluate efficacy and toxicity of cetuximab plus cisplatin in recurrent or metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT) after previous platinum based ch...

Keywords:

Cetuximab
Carcinoma
Oncology
Pathology
Cisplatin
Internal medicine
Medicine
open label
Toxicity
undifferentiated carcinoma
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations